financial guidance

Core revenues grew 4 percent year over year, but the firm missed Wall Street analyst estimates on both the top and bottom lines.

The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.

The liquid biopsy firm beat analyst estimates on the top and bottom lines and raised full-year revenue guidance to $145 to $150 million.

The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.

The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.

Within diagnostics, molecular revenues were up 11 percent year over year to $167.8 million. The firm received two new CE marks for early infant diagnosis and testing dried blood spots.

For the quarter ended March 31, Twist reported $13.6 million in revenues, up from $6.2 million during the same period last year.

It placed 39 net new ePlex analyzers, expanding the global installed base to 393 placements and growing its installed base by 72 percent compared to the prior-year period.

The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.

The company increased its 2019 revenue forecast and shrunk its net loss significantly in its push to become cash flow breakeven by the end of the year.